Liraglutide Dosage Guide: Daily GLP-1 Protocol & Reconstitution Explained
Liraglutide
Liraglutide is a GLP-1 receptor agonist used clinically for type 2 diabetes and chronic weight management. It helps regulate appetite, food intake, glucose-dependent insulin signaling, and gastric emptying. Unlike longer-acting GLP-1 medications such as semaglutide, liraglutide is administered once daily.
How It Works
GLP-1 Receptor Activation → Satiety ↑ + Food Intake ↓ + Glucose Regulation ↑ → Weight & Metabolic Effects
Liraglutide activates GLP-1 receptors, which increases satiety, reduces food intake, supports glucose-dependent insulin secretion, and slows gastric emptying. Because its duration of action is shorter than once-weekly GLP-1 medications, approved liraglutide products are administered daily.
Liraglutide is a GLP-1 receptor agonist.
Approved products are administered once daily by subcutaneous injection.
Dose escalation is gradual to reduce gastrointestinal side effects.
Clinical dose targets differ depending on whether liraglutide is being used for diabetes or chronic weight management.
Liraglutide Dosing Protocol
Important Evidence Distinction:
The milligram dose-escalation schedule below follows established clinical liraglutide dosing. The syringe-unit conversions apply only to the example 5 mg research vial reconstituted to 2.5 mg/mL and should not be confused with the manufactured concentration of FDA-approved liraglutide pens.
The milligram dose-escalation schedule below follows established clinical liraglutide dosing. The syringe-unit conversions apply only to the example 5 mg research vial reconstituted to 2.5 mg/mL and should not be confused with the manufactured concentration of FDA-approved liraglutide pens.
0.6 mg → 1.2 mg → 1.8 mg → 2.4 mg → 3.0 mg Daily
Example Research-Vial Setup
Vial
5 mg
Water
2.0 mL bacteriostatic water
Concentration
2.5 mg/mL
Conversion
1 unit = 25 mcg
Week 1
Starting Dose
Dose
0.6 mg daily
Units
24 units
Volume
0.24 mL
Week 2
Build Phase
Dose
1.2 mg daily
Units
48 units
Volume
0.48 mL
Week 3
Higher Clinical Dose
Dose
1.8 mg daily
Units
72 units
Volume
0.72 mL
Week 4
Weight-Management Escalation
Dose
2.4 mg daily
Units
96 units
Volume
0.96 mL
Week 5+
Weight-Management Target
Dose
3.0 mg daily
Units
120 units
Volume
1.20 mL
Volume Note:
At the example concentration of 2.5 mg/mL, a 3.0 mg amount equals 1.20 mL or 120 units. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example research-vial concentration, not of the clinical liraglutide dose itself.
At the example concentration of 2.5 mg/mL, a 3.0 mg amount equals 1.20 mL or 120 units. That exceeds the capacity of a standard 1 mL U-100 insulin syringe. This is a limitation of the example research-vial concentration, not of the clinical liraglutide dose itself.
Diabetes vs Weight-Management Dosing
Type 2 Diabetes Context
Starting Dose
0.6 mg daily
Typical Dose
1.2 mg daily
Maximum Victoza Dose
1.8 mg daily
Chronic Weight-Management Context
Week 1
0.6 mg daily
Week 2
1.2 mg daily
Week 3
1.8 mg daily
Week 4
2.4 mg daily
Week 5+
3.0 mg daily
Why the distinction matters:
The 1.8 mg and 3.0 mg dose ceilings come from different approved liraglutide indications. A page discussing both diabetes and obesity should not imply that 1.8 mg is the universal maximum liraglutide dose.
The 1.8 mg and 3.0 mg dose ceilings come from different approved liraglutide indications. A page discussing both diabetes and obesity should not imply that 1.8 mg is the universal maximum liraglutide dose.
How to Use Liraglutide (Timing & Injection)
FrequencyOnce daily
RouteSubcutaneous
Time of DayAny time of day
FoodWith or without food
Treatment StyleOngoing treatment rather than short cycling
Injection Guidance
Approved liraglutide is administered subcutaneously.
Common injection regions include the abdomen, thigh, and upper arm.
Rotate injection sites regularly.
A specific morning or evening advantage has not been established.
Using a consistent daily routine can make adherence easier.
Why Dosing Is Increased Gradually
Gastrointestinal adverse effects are common during treatment initiation and dose escalation.
Weekly escalation allows time to assess nausea, vomiting, diarrhea, constipation, abdominal symptoms, and appetite reduction.
The lower 0.6 mg dose is primarily used to improve tolerability during treatment initiation.
Dose escalation should not be accelerated simply to reach a higher target sooner.
Clinical Evidence
SCALE Obesity & Prediabetes
Dose
3.0 mg once daily
Duration
56 weeks
Participants
3,731 adults
Weight-Loss Findings
Participants receiving liraglutide 3.0 mg lost an average of approximately 8.4 kg at 56 weeks compared with approximately 2.8 kg with placebo.
Approximately 63.2% of participants receiving liraglutide lost at least 5% of their starting body weight compared with 27.1% receiving placebo.
Approximately 33.1% receiving liraglutide lost more than 10% of their starting body weight compared with 10.6% receiving placebo.
Gastrointestinal effects, particularly nausea and diarrhea, were among the most frequently reported adverse events.
Human Evidence:
Unlike many experimental peptides, liraglutide has extensive controlled human clinical data supporting both glucose-lowering and weight-management effects at indication-specific doses.
Unlike many experimental peptides, liraglutide has extensive controlled human clinical data supporting both glucose-lowering and weight-management effects at indication-specific doses.
Reconstitution & Dose Conversion (5 mg Vial)
Research-Vial Context:
FDA-approved liraglutide products are manufactured ready-to-use injection solutions and do not require bacteriostatic-water reconstitution. The calculations below apply only to the example 5 mg research-vial setup.
FDA-approved liraglutide products are manufactured ready-to-use injection solutions and do not require bacteriostatic-water reconstitution. The calculations below apply only to the example 5 mg research-vial setup.
Example Research-Use Setup
Vial5 mg
Water2.0 mL bacteriostatic water
Concentration2.5 mg/mL
Conversion1 unit = 25 mcg
Dose Reference
24 units = 0.6 mg
48 units = 1.2 mg
72 units = 1.8 mg
96 units = 2.4 mg
120 units = 3.0 mg
Research-Vial Handling
Add the selected sterile diluent slowly to the vial
Gently swirl rather than shaking vigorously
Allow the material to dissolve completely
Label the vial with concentration and preparation date
Follow formulation-specific storage information when available
Storage & Shelf Life
FDA-Approved Liraglutide
Approved liraglutide products should be stored according to their specific manufacturer labeling.
Manufactured liraglutide pens are ready-to-use formulations and should not be handled like generic lyophilized peptide vials.
Research-Vial Context
Lyophilized research material is commonly stored cold, dry, sealed, and protected from light according to supplier specifications.
Reconstituted research preparations are commonly refrigerated.
A universal 30-day post-reconstitution shelf life should not be assumed for every independently prepared liraglutide formulation.
Stability depends on formulation, concentration, diluent, sterility, container, and manufacturer specifications.
Cycle Length & Long-Term Use
Daily Treatment → Monitor Response → Continue, Adjust, or Discontinue as Appropriate
Treatment Context
Use Style
Long-term treatment
Routine Cycling
Not generally required
Fixed 8–12 Week Review
Not a required clinical cycle
Continuation
Based on indication, response, tolerability, and clinical goals
Why this is different:
Liraglutide is an established chronic-treatment medication rather than a short-cycle research peptide. Clinical trials have studied continuous daily treatment for a year or longer rather than routine on/off cycling.
Liraglutide is an established chronic-treatment medication rather than a short-cycle research peptide. Clinical trials have studied continuous daily treatment for a year or longer rather than routine on/off cycling.
Monitoring During Use
Body weight and waist circumference when used for weight management
Appetite, satiety, and nutritional intake
Blood glucose and A1C when clinically relevant
Nausea, vomiting, diarrhea, constipation, and abdominal symptoms
Hydration status if GI symptoms are significant
Signs or symptoms of gallbladder disease or pancreatitis
Hypoglycemia risk when used with insulin or insulin-secretagogue medications
Benefits & Clinical Findings
Reduces appetite and food intake through GLP-1 receptor signaling.
Large randomized trials demonstrate clinically meaningful weight reduction with 3.0 mg daily.
Improves glycemic control in people with type 2 diabetes.
Clinical studies have reported improvements in multiple cardiometabolic risk markers.
Daily administration provides consistent GLP-1 receptor activity.
Potential Side Effects & Safety Considerations
Nausea is among the most common adverse effects, particularly during titration.
Vomiting, diarrhea, constipation, dyspepsia, and abdominal symptoms can occur.
Gallbladder-related events and pancreatitis are important clinical safety considerations.
Dehydration and kidney problems can occur secondary to persistent vomiting or diarrhea.
Hypoglycemia risk increases when liraglutide is combined with insulin or medications that stimulate insulin secretion.
Liraglutide carries a boxed warning regarding thyroid C-cell tumors based on animal findings and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or MEN2.
Important Notes
Liraglutide is an established GLP-1 receptor agonist with extensive human clinical research.
It is administered once daily rather than once weekly.
The approved dose ceiling depends on indication: up to 1.8 mg daily for Victoza and 3.0 mg daily for Saxenda.
The established Saxenda escalation schedule is 0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg daily, generally increasing once per week.
The lower 0.6 mg dose is primarily an initiation dose used to improve gastrointestinal tolerability.
Liraglutide is generally used as long-term pharmacotherapy rather than being routinely cycled on and off.
The 5 mg vial + 2.0 mL BAC-water example shown on this page is research-vial math and is not the formulation used in FDA-approved pens.
Nutrition, hydration, and GI tolerance remain important when appetite and food intake are substantially reduced.
Important Disclaimer
Liraglutide is an FDA-approved prescription medication for specific indications. The research-vial concentration and reconstitution examples shown on this page are educational and should not be confused with the manufactured formulation or prescribing instructions for approved liraglutide products.
Research & References
Primary Research
- Marre M, Shaw J, Brändle M, et al. Liraglutide, a Once-Daily Human GLP-1 Analogue, Added to a Sulphonylurea Over 26 Weeks Produces Greater Improvements in Glycaemic and Weight Control Compared with Adding Rosiglitazone or Placebo in Subjects with Type 2 Diabetes (LEAD-1 SU). Diabetic Medicine. 2009.
- Pi-Sunyer X, Astrup A, Fujioka K, et al. A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine. 2015.
- Davies MJ, Bergenstal R, Bode B, et al. Efficacy of Liraglutide for Weight Loss Among Patients With Type 2 Diabetes: The SCALE Diabetes Randomized Clinical Trial. JAMA. 2015.
Reviews & Supporting Research
Research Note: Liraglutide dosing protocols are based on the FDA-approved titration schedules used in the LEAD and SCALE clinical trial programs for Victoza® (type 2 diabetes) and Saxenda® (chronic weight management).
Comments
Post a Comment